Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan-Mar;3(1):60-3.

Primary immunodeficiencies of the B lymphocyte

Affiliations
Review

Primary immunodeficiencies of the B lymphocyte

Ana Moise et al. J Med Life. 2010 Jan-Mar.

Abstract

The immune response consists of two main components: humoral immunity represented by B lymphocytes and cellular immunity maintained by the T lymphocytes. Immunoglobulins, produced by B-lymphocytes, are the main mediators of humoral immunity, and deficiencies at this level affect the body's response to infection. Plasmocytes produce nine antibody izotypes: immunoglobulins G (IgG1, IgG2, IgG3, IgG4), immunoglobulins M (IgM), immunoglobulins A (IgA1, IgA2), immunoglobulins D (IGD) and immunoglobulins E (IgE). Primary hypogammaglobulinemias are characterized by the occurrence of recurrent infections and, paradoxically, by the occurrence of autoimmune diseases. Characteristic for these diseases is that symptoms occur at 7-9 months after birth, when transplacental antibody titers transmitted from the mother decrease, and the infant's body is unable to synthesize them to normal levels. Primary hypogammaglobulinemias are transmitted genetically, but mutations at the molecular level are still not fully understood. The most common are: Bruton agammaglobulinemia, transient newborn hypogammaglobulinemia, selective immunoglobulin deficiency and variable common immunodeficiency. Treatment consists of monthly antibiotics and immunoglobulins, depending on antibody titers (except for IgA deficiency).

PubMed Disclaimer

Similar articles

  • [Humoral immunodeficiency : awareness for better support].
    El Bakkouri J, Aadam Z, Ailal F, Alj HS, Bousfiha AA. El Bakkouri J, et al. Pan Afr Med J. 2014 Aug 4;18:272. doi: 10.11604/pamj.2014.18.272.4061. eCollection 2014. Pan Afr Med J. 2014. PMID: 25489366 Free PMC article. Review. French.
  • Assessment and clinical interpretation of reduced IgG values.
    Agarwal S, Cunningham-Rundles C. Agarwal S, et al. Ann Allergy Asthma Immunol. 2007 Sep;99(3):281-3. doi: 10.1016/S1081-1206(10)60665-5. Ann Allergy Asthma Immunol. 2007. PMID: 17910333 Free PMC article. No abstract available.
  • Immunodeficiency.
    Justiz Vaillant AA, Qurie A. Justiz Vaillant AA, et al. 2023 Jun 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jun 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 29763203 Free Books & Documents.
  • Antibody Deficiency Disorder (Archived).
    Justiz Vaillant AA, Ramphul K. Justiz Vaillant AA, et al. 2023 May 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 May 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 29939682 Free Books & Documents.
  • Isotype deficiencies (IgG subclass and selective IgA, IgM, IgE deficiencies).
    Imam K, Huang J, White AA. Imam K, et al. Allergy Asthma Proc. 2024 Sep 1;45(5):317-320. doi: 10.2500/aap.2024.45.240055. Allergy Asthma Proc. 2024. PMID: 39294903 Review.

Cited by

References

    1. Khan WN. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase . Immunol Res. 2001;23:147–156. - PubMed
    1. Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B–cell development and function: a genetic perspective. Immunol Rev. 2000;175:120–127. - PubMed
    1. Chun JK, Lee TJ, Song JW, Linton JA, Kim DS. Analysis of clinical presentations of Bruton disease: a review of 20 years of accumulated data from pediatric patients at Severance Hospital. Yonsei Med J. 2008;49:28–36. - PMC - PubMed
    1. Freeman AF, Holland SM. Persistent bacterial infections and primary immune disorders. Curr Opin Microbiol. 2007;10:70–75. - PubMed
    1. Ballow M. Safety of IGIV therapy and infusion–related adverse events. Immunol Res. 2007;38:122–132. - PubMed

MeSH terms

Substances

LinkOut - more resources